Our News
All the latest company news, views and insight from the Beckley Psytech team.
Wearable technology can revolutionise our clinical research
Becky Hutchinson, commercial director at Beckley Psytech
News article on the appointment of Andy Page as Beckley Psytech’s new Chief Operating Officer.
Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer
Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer with immediate effect.
Article on Beckley Psytech receiving UK Clinical Trial Authorisation to explore the effects of psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA), featuring a quote from Dr Fiona Dunbar, Chief Medical Advisor.
Beckley Psytech receives approval for clinical trial using psychedelic agent to treat severe headach...
Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has received Clinical Trial Authorisation (CTA) from the UK Medicine and Healthcare Products Regulatory Agency (MHRA) to e... Read More
Article on the prospects for the psychedelic drugs market with comments from Beckley Psytech CEO Cosmo Feilding-Mellen following the news of the company’s latest £14m funding round.
News article on the £14m funding round to finance a drug development pipeline for 5-MeO-DMT, featuring quotes from CEO Cosmo Feilding-Mellen and investor James Bailey from Bail Capital.
News article on the successful latest funding round to finance Beckley’s lead development programme on synthetic 5-MeO-DMT.
Exclusive news article on the $18.6m funding round, featuring Beckley Psytech’s pitch deck and comments from CEO Cosmo Feilding-Mellen.